Tweets
When to use #belimumab and when to use #voclosporin? Dr. Dall'Era does the following:
Belimumab: GFR<45, low proteinuria, extrarenal dz, pt factors
Voclosporin: GFR>45 w/o sig chronicity, high level proteinuria (3+g/), pt preference for oral
#ACR23 #MeetExpert @rheumnow https://t.co/0SXRBtChfk
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
"Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn't you want to get rid of the whole cancer!" - Dr. M Petri on how we should view lupus nephritis #ACR23 @rheumnow #MeetExpert
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered long-term, med-free remission in 1 dose in LN and SLE. More studies needed! #ACR Abs 1493 @rheumnow https://t.co/sT68cN3TKe
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
ACR#23 Abs #1023: IgG4-RD males > likely (vs females) to have multi-organ & serological activity w/ ^ immunoglobulin concentrations. Interestingly, lower lipase levels observed in males are consistent with greater degrees of pancreatic damage. https://t.co/4hUGmzTQqX @rheumnow https://t.co/kcy5dL62Pn
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
UTSW Dallas study: Health literacy may be essential limiting factor for families w/ children w/ SLE. Other critical barriers to patient care include food security and living costs such as transportation, housing, and utilities. #ACR23 Abs #1029 https://t.co/jtnIgLZQfC @rheumnow https://t.co/A1zr8quSdd
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
RheumNow Live registration is open! Join us this January!
https://t.co/x3ilRUi1hX https://t.co/7fBLaYwIiT
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
LV mass higher in pts with SLE nephritis.Nested case-control study 48 SLE pts +/- LN. LV mass higher w/LN (66.9 g/m2) vs pts w/o LN (54.8 g/m2, p=0.035). Higher LV mass may increase risk for CV events as CHF, arrhythmias and CV mortality. @RheumNow #ACR23 abst#1447
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Real World SLE Rx patterns from the SPOCS cohort. 70+% IFN high, 81% on antimalarials, 21% biologics, and 55% IS, 65% GCs. High IFN pts had more IS and steroid use. 45+% still on GCs at 12 months despite avail of new therapeutics @RheumNow #ACR23 abst#0592
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Assessment of MAP kinase pathway gene expression prior to tx may aid in identification of polyarticular course JIA patients that could exhibit poor response to tofacitinib. It may be helpful in personalized tx algorithm! #ACR23 Abs #0830 https://t.co/Z8pykbG7x5 @rheumnow https://t.co/ANZr8aVrVB
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic first tx at the 2-3 yr timeframe for pJIA pts. More data needed to optimize outcomes/tx for these children. https://t.co/vWL5J4FPbo #ACR23 @rheumnow https://t.co/5iJpwglhPu
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
Vasc Events in Danish Cohort: 3178 SLE pts matched to 60K controls. MI in SLE 2.9% vs 1.4%, cerebrovascular dz 7% vs 2.7%, & PVD 5.5% vs 1.4%. IRR ranged 1.7-7.6. Female SLE pts had 3-5X risk for CVE, Male pts 6-8X risk. @RheumNow #ACR23 abst#1442 https://t.co/PapDiJ0shJ
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Obintuzumab in Lupus Nephritis
Researchers found that treatment with obinutuzumab was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis.
https://t.co/Sbh6k6XKjz https://t.co/aDbLUh7WtM
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
